Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Rottlerin: Bases for a Possible Usage in Psoriasis

Author(s): Emanuela Maioli and Giuseppe Valacchi

Volume 11, Issue 5, 2010

Page: [425 - 430] Pages: 6

DOI: 10.2174/138920010791526097

Price: $65

Abstract

Rottlerin is a natural polyphenolic compound, which was initially indicated and marketed as a PKC δ inhibitor and recently proposed and patented as an anti-hypertensive drug. In vitro results from our Laboratory and data from the literature suggest a potential use of Rottlerin in the treatment/control of psoriasis, a skin disease characterized by abnormal cellular proliferation, abnormal angiogenesis and inflammation. Rottlerin, indeed, is an antioxidant and a potent inhibitor of the transcription factor NFκB, a key mediator of immune responses and a crucial regulator of cell cycle and apoptosis in immune cells, endothelial cells and keratinocytes. Herein, we will review the multiple activities of Rottlerin (antioxidant, antiproliferative, antiangiogenic and anti-inflammatory) that give to the drug the potential to be used as a new therapeutic approach against psoriasis.

Keywords: Rottlerin, NFκB, Inflammation, Angiogenesis, Proliferation


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy